Roche Diagnostics, Ltd, Rotkreuz, Switzerland.
Mol Diagn Ther. 2011 Jun 1;15(3):129-41. doi: 10.1007/BF03256403.
Colorectal cancer (CRC) persists as one of the most significant causes of cancer death worldwide. Recent progress in reducing cancer mortality can largely be attributed to the implementation of screening programs. However, screening programs have not realized their full potential for the reduction of CRC mortality, because of poor adherence rates among patients. Serum biomarker screening tests offer the potential for improved patient adherence to CRC screening programs. In this review, we assess the literature regarding serum biomarkers for use as CRC screening tests for colorectal cancer and adenomas. A systematic review was performed of Medline-indexed articles pertaining to serum biomarkers for CRC screening published within the past 4 years. In addition, we searched non-Medline sources for information pertaining to screening guidelines and practice patterns for CRC. We identified 51 articles from Medline pertaining to serum biomarkers as screening tests for CRC. Non-Medline sources yielded an additional 12 articles, for a total of 63 publications reviewed. We conclude that serum tests that involve simple blood draws during routine check-ups hold significant promise for improving patient acceptance and adherence to CRC screening.
结直肠癌(CRC)仍然是全球癌症死亡的主要原因之一。最近在降低癌症死亡率方面取得的进展在很大程度上归因于筛查计划的实施。然而,由于患者的依从率低,筛查计划尚未充分发挥其降低 CRC 死亡率的潜力。血清生物标志物筛查测试为提高患者对 CRC 筛查计划的依从性提供了潜力。在这篇综述中,我们评估了有关血清生物标志物作为结直肠癌和腺瘤 CRC 筛查测试的文献。对过去 4 年内发表的关于用于 CRC 筛查的血清生物标志物的 Medline 索引文章进行了系统评价。此外,我们还搜索了非 Medline 来源的有关 CRC 筛查指南和实践模式的信息。我们从 Medline 中确定了 51 篇与 CRC 筛查的血清生物标志物有关的文章。非 Medline 来源又提供了另外 12 篇文章,共审查了 63 篇出版物。我们的结论是,在常规体检期间进行简单采血的血清检测在提高患者对 CRC 筛查的接受度和依从性方面具有重要意义。